Key Highlights

  • AVITA Medical (NASDAQ:RCEL) gained 40.33% over one month in published market data as of October 28, 2026, and is up 269.23% over three months and 367.62% year to date.
  • No single announcement explaining the monthly move was found; BTIG raised its target to USD 15 from USD 11 with a Buy rating on October 12, 2026.
  • Second quarter revenue was a record USD 21.7 million, up 18% year over year, and 2026 revenue guidance was raised to USD 86 million to USD 89 million from USD 80 million to USD 85 million.
  • Management expects cash flow breakeven in the fourth quarter of 2026, with cash of about USD 11.1 million at June 30, a thin cushion for AVITA Medical (NASDAQ:RCEL).

Why the Stock Moved

AVITA Medical (NASDAQ:RCEL) announced no deal or financing in October 2026 that explains the 40.33% gain, which follows a 269.23% rise over three months. The identified items are analyst actions: BTIG raised its target to USD 15 from USD 11 with a Buy rating on October 12, Lake Street raised to USD 12 from USD 8 on August 28, and TD Cowen raised to USD 14 from USD 12 on August 19. Consensus is five Buy, one Hold and one Sell with an average target of USD 12.20, below the latest USD 16.32. On October 20 the company announced it will report third quarter results. Lake Street and TD Cowen both carry Buy ratings, while Weiss Ratings reiterated a sell rating on September 21.

Second Quarter Numbers

On August 6, 2026 the company reported record second quarter revenue of USD 21.7 million, up 18% year over year and 13% sequentially. Gross margin was 81.9% and the net loss narrowed to USD 7.7 million, or USD 0.25 per share, from USD 9.9 million. RECELL revenue was USD 18.5 million, Cohealyx USD 1.7 million, up about 16% sequentially, and PermeaDerm USD 0.6 million, up about 40%. Raised 2026 guidance of USD 86 million to USD 89 million implies 20% to 24% growth over 2025 revenue of USD 71.6 million. Favorable interim data from the Cohealyx I study in April showed faster time to skin grafting readiness than leading competitors, and the company expected PermeaDerm I study data in August.

Risks and Next Steps

Cash of about USD 11.1 million at June 30 is small, although net cash use fell to about USD 3.2 million in the quarter from USD 9.9 million, and management expects breakeven in the fourth quarter, which has to be delivered. After a 277.78% six-month gain, the stock trades above the average analyst target, so a miss could reverse it. Beta is reported near 2.0, which means large swings. A financing would dilute holders of AVITA Medical (NASDAQ:RCEL). Investors should watch the third quarter report and cash flow. Cash use fell as revenue grew, but a shortfall in the fourth quarter would likely require new funding.

Where Things Stand

AVITA Medical (NASDAQ:RCEL) gained 40.33% because investors are rewarding record revenue growth of 18%, raised 2026 guidance and a path to cash flow breakeven, with BTIG adding a USD 15 target on October 12, 2026. No single October announcement explains it. The risk is valuation and funding: the stock trades above the USD 12.20 average target and cash was about USD 11.1 million at June 30. The next test is the third quarter report and whether breakeven stays on track.